Glucose-responsive insulin - Sensulin
Latest Information Update: 26 Jun 2024
At a glance
- Originator Sensulin
- Class Antihyperglycaemics; Hepatoprotectants; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 26 Jun 2024 Preclinical trials are still ongoing in Diabetes mellitus in USA (Parenteral) (Sensulin pipeline, June 2024)
- 28 Mar 2023 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA (Parenteral, Injection)
- 05 Feb 2019 Glucose-responsive insulin - Sensulin is available for licensing as of 05 Feb 2019. https://www.sensulin.com/